MARKET-READY PORTFOLIO

Scalable Regenerative Solutions.

MimiX AWC is a commercial-stage biotherapeutics company. We manufacture and sell a modular ecosystem for advanced wound care. Building on the commercial success of the FastSkin® Patch, we are expanding our portfolio with active technologies to standardise autologous therapies globally.

INDUSTRIAL ENGINE

Sound Induced Morphogenesis (SIM)

Powering our next-generation products is SIM technology. This proprietary industrial method uses specific acoustic frequencies to organize biological matter instantly.

It creates a unique competitive advantage: the ability to manufacture complex, vascularized tissue structures in seconds at the point of care, surpassing the limitations of traditional manufacturing methods.

SCIENTIFIC VALIDATION

Evidence for Autologous Blood Clot Therapy

The FastSkin® Patch is built upon a clinically proven therapeutic modality. The efficacy and safety of topical autologous whole blood clots are extensively supported by peer-reviewed literature in the field of wound care.

Health Economics

Economic Value of the Modality

WOUNDS

Published data suggests that topical autologous blood clot therapy offers a lower cost per healed wound compared to other advanced skin substitutes, driving value for healthcare systems.

Outcomes for Venous Leg Ulcers

Registry Studies

Clinical registries indicate that applying a whole blood clot matrix effectively reactivates the healing cycle in hard-to-heal VLUs by providing a temporary scaffold and restoring biological signaling.

Efficacy in Diabetic Foot Ulcers

Journal of Wound Care, 2024

Multicentre RCTs on autologous blood clot therapy have demonstrated significantly higher healing rates and shorter time to heal compared to standard of care alone in complex DFU cases.

Distribute Our Solutions

We are expanding our global commercial footprint. Join our network of distributors and clinical partners to bring these innovations to your market.